Reports Q3 revenue $5.07B, consensus $4.97B. “We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific (BSX). “As we shared at our recent Investor Day meeting, we are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Notable companies reporting before tomorrow’s open
- Boston Scientific (BSX) Q3 Earnings Cheat Sheet
- Boston Scientific gets another winner with Nalu acquisition, says Leerink
- Boston Scientific’s Strategic Acquisition of Nalu Medical: A Growth Opportunity in the Neuropathic Pain Market
- Boston Scientific to acquire Nalu Medical for upfront cash payment of ~$533M